ProMIS Neurosciences (PMN) Q3 2026 earnings review
ProMIS cuts trial spending, but its key Alzheimer's test awaits
ProMIS Neurosciences, a developer of antibody drugs for brain diseases, is spending less cash as its Alzheimer's trial wraps up. Research costs fell 32% from a year ago because patient visits in its Phase 1b study are nearly finished, lowering the quarterly net loss to $8 million. Chief executive Neil Warma kept the first-quarter 2027 data schedule and the 2027 cash outlook, which by our math allows under $9 million of cash use per quarter.
| Cash and short-term investments | $44.1M down $9.4M from last quarter by our math |
|---|---|
| Research and development costs | $6.7M -32% from a year ago |
| Net loss | $8.2M $11.6M a year ago |
| Cash runway outlook | Unchanged funded through 2027 (implies ≤$8.8M/qtr burn) |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because everything still rests on the unblinded Alzheimer's trial results due in the first quarter of 2027. On the positive side, the drop in trial spending makes the 2027 cash plan believable for routine operations, and hiring a commercial chief prepares the group for next steps. One caution: the company defined an encouraging memory result as matching existing drugs rather than beating them, and its current cash cannot pay for the final-stage trial it hopes to start in late 2027.
The question now is whether the 15% drop in Alzheimer's blood markers seen in July's blinded data came from the drug or from noise in the pooled patient group. Either the unblinded data will show clear separation from the dummy treatment alongside clean brain scans, or weak separation will leave the company short of the warrant cash it needs for a final-stage trial. The unblinded 12-month readout in the first quarter of 2027 will settle it.
🐂 Bull Case
Winding Down Trial Visits Cut Research Spending
ProMIS Neurosciences is a clinical-stage biotechnology group developing PMN310, an experimental antibody drug for Alzheimer's disease. To make its cash last through 2027, the company needed spending on its Phase 1b clinical trial, PRECISE-AD, to drop as patient treatment wraps up.
That drop arrived in the third quarter. Research and development costs fell 31.5% from a year ago to $6.7 million because direct spending on PMN310 dropped by $3.6 million as the study "progressed toward completion of patient visits during 2026".
- Research and development costs: $6.7 million, down 29.5% from last quarter
- Total operating loss: $8.6 million, down from $12.3 million in the second quarter
- Net cash used: $9.4 million by our math, down from $10.4 million last quarter
Lower trial bills brought total operating expenses down to $8.6 million. Because the group also earned $0.5 million in interest on its cash, its quarterly net loss before bill paydowns is now below the $8.8 million quarterly cash use ceiling implied by its 2027 outlook.
What to watch: fourth-quarter research and development spending after the final patient visits finish. A further drop will confirm that ongoing overhead is low enough to stretch existing cash through the end of 2027.
Commercial Hire and Injection Work Back Late-Stage Plan
Chief executive Neil Warma believes PMN310 can avoid ARIA, the brain swelling and bleeding linked to approved Alzheimer's drugs, because it targets only toxic protein clusters called oligomers and ignores plaque. In July, blinded six-month data from 136 patients showed zero cases of brain swelling.
To prepare for what comes after the trial, ProMIS hired Dr. Ivana Rubino, a former Biogen and Roche neuroscience leader, as chief commercial officer in October. The biotech developer is also developing an under-the-skin injection version of PMN310 "to support patient convenience and access" for its next clinical study.
What to watch: the outcome of the planned meeting with the US Food and Drug Administration in 2027 after the first-quarter trial readout. Agency agreement to let the group test the new injection in a single final-stage trial would speed up development.
🐻 Bear Case
The Late-2027 Trial Plan Exceeds the Cash Budget
ProMIS ended September with $44.1 million in cash and short-term investments, which it says will fund its operating plan through the end of 2027. At the same time, Warma said the company is preparing for a final-stage registrational study of PMN310 that it anticipates "initiating toward the end of 2027".
By our math, $44.1 million spread across the five quarters from October 2026 through December 2027 allows an average cash burn of $8.8 million per quarter. In the third quarter, net cash burn was $9.4 million by our math because the group paid down $1.9 million in unpaid bills alongside its $8.2 million net loss.
That $8.8 million quarterly allowance covers only routine company overhead and winding down the current Phase 1b study. Starting a large registrational trial and manufacturing the new under-the-skin injection in late 2027 will require new funding, either from a partner, a stock sale, or investors exercising up to $100 million of warrants after the first-quarter data.
What to watch: cash inflow from the 6.9 million warrants that expire 60 days after the first-quarter 2027 trial results. If those warrants bring in no cash, ProMIS will need to raise money before it can start its next trial.
Management Reset the Efficacy Target to Matching Rivals
Last quarter, Warma told investors on the conference call that the company expected improved efficacy compared with Alzheimer's drugs already on the market. In this release, Warma said PMN310 could "take a leadership position" if it shows brain-swelling rates like a dummy treatment and, "at a minimum, similar efficacy".
The company's formal criteria for the first-quarter 2027 readout now define an encouraging result as slowing cognitive decline at a rate "similar to existing therapies at 12 months" on standard memory scales (iADRS or CDR-SB). Setting the bar at matching existing treatments contradicts last quarter's talk of beating them, and the current 144-patient study is designed around safety rather than proving a small difference in memory scores.
What to watch: the difference in 12-month memory scores and blood markers (such as pTau217) between PMN310 and the dummy treatment in the first quarter of 2027. A weak separation on memory scores would leave the drug relying on safety alone against established rivals.
Early ALS and Parkinson's Drugs Still Await Final Testing
Alongside its Alzheimer's drug, ProMIS promotes a broader pipeline led by PMN267 for amyotrophic lateral sclerosis (ALS, a nerve-wasting disease) and PMN442 for Parkinson's disease and related brain disorders. Management said last quarter that both antibodies would be ready within six to nine months for IND-enabling studies, the final laboratory safety tests required before human trials.
In the third quarter, the release described PMN442 as ready "for advancement to IND-enabling studies", nearly the same wording used since mid-2025, while vaccine candidates PMN311, PMN440 and PMN260 remain in mouse testing. Although the company noted higher activity in its ALS and platform programs, neither antibody has entered formal pre-human safety testing yet, leaving the business dependent on PMN310.
What to watch: an announcement by the second quarter of 2027 that PMN267 or PMN442 has officially started IND-enabling toxicology studies. Another quarter without starting those studies would show that cash conservation is holding back the rest of the pipeline.
Risks this quarter didn't answer
Four standing clinical and financial concerns received no new data in the third-quarter release because the PRECISE-AD trial remains blinded until early 2027.
- Unblinded drug effect: whether the 15% drop in blood marker pTau217 and 13.3% drop in spinal-fluid marker MTBR-tau243 came from PMN310 rather than the dummy group will be answered in the first-quarter 2027 readout.
- Full 12-month brain scan safety: half of the patients had not finished 12 months of treatment at the July cutoff, so final rates of brain swelling and bleeding wait for the first-quarter 2027 data.
- Potential share dilution: the 9.34 million warrants and $50 million share-sale program from prior filings remain in place until the 60-day warrant window closes after the readout.
- Oligomer test accuracy: the release cited Phase 1a spinal-fluid binding data presented at a summer conference, but published no laboratory controls proving the drug itself does not interfere with the test.
💲 Other KPIs
Overhead costs fell 2.4% from a year ago and dropped 30.6% from the second quarter. Last quarter's $2.74 million bill was inflated by mid-year employee bonuses; in the third quarter, lower consulting fees offset higher staff salaries from new hires.
Unpaid bills and accrued clinical trial expenses fell 26.0% from last quarter's $7.22 million and are down 48.7% from $10.41 million at the end of 2025. Paying down $1.87 million of these short-term liabilities in the third quarter kept cash burn above the operating loss.
Share count was almost unchanged from 9.14 million in the second quarter, but rose 368.1% (4.7 times) from 1.95 million a year ago following the January 2026 private share sale. That larger share count accounted for most of the drop in per-share net loss from $5.93 to $0.89.
🔮 Guidance
Unchanged. ProMIS still expects its $44.1 million in cash to fund its operating plan through the end of 2027, well past the first-quarter 2027 Alzheimer's trial readout. By our math, that leaves a maximum average cash use of $8.8 million per quarter across the next five quarters, compared with $9.4 million used in the third quarter.
Unchanged. The group continues to expect all 144 enrolled Alzheimer's patients to finish their 12-month treatment visits in the fourth quarter of 2026, matching the schedule held since late 2025.
Unchanged. Management reaffirmed that unblinded 12-month safety, blood and spinal-fluid markers, and memory test results will arrive in the first quarter of 2027. The timeline had previously shifted once from late 2026 after the study expanded enrollment from 128 to 144 patients.
❓ Key Questions
What will quarterly cash burn be after patient visits end?
Research costs fell to $6.7 million in Q3 as patient visits wound down. Investors need to know the baseline quarterly burn for 2027 and whether the through-2027 cash plan includes any spending for the registrational study planned for late 2027.
How will ProMIS fund the late-2027 study without warrants?
Up to $100 million in warrant proceeds depend on the first-quarter 2027 trial results and expire 60 days after the readout. If those warrants expire unused, management must clarify whether it will seek a partner or issue new shares.
What exact memory and biomarker differences will define Phase 1b success?
The release defines encouraging efficacy as directional slowing of decline similar to existing therapies on iADRS or CDR-SB. Because the 144-patient trial was sized to detect brain swelling rather than small memory differences, investors need the specific target thresholds by dose.
When will PMN267 and PMN442 enter formal pre-human safety studies?
Both the ALS and Parkinson's antibodies have been described as advancing toward IND-enabling studies since mid-2025. Management has not stated the cost of those toxicology studies or whether they are on hold until after the Alzheimer's readout.